MaxCyte Inc 2026年季度报告

FORM10-Q (Mark one) ☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period from___ to___Commission File Number: 001-40674 MaxCyte,Inc.(Exact name of registrant as specified in its charter) Delaware52-2210438(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) 9713 Key West Avenue, Suite400Rockville, Maryland 20850(Address of principal executive offices including zip code) Registrant’s telephone number, including area code: (301) 944-1700 N/A(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section12(b)of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the SecuritiesExchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports),and (2)has been subject to such filing requirements for the past 90days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No☒ Table of Contents NoPARTI. FINANCIAL INFORMATION3Item1.Condensed Consolidated Financial Statements (Unaudited)3Condensed Consolidated Balance Sheets3Condensed Consolidated Statements of Operations4Condensed Consolidated Statements of Changes in Stockholders’ Equity5Condensed Consolidated Statements of Cash Flows6Notesto Unaudited Condensed Consolidated Financial Statements7Item2.Management’s Discussion and Analysis of Financial Condition and Results ofOperations17Item3.Quantitative and Qualitative Disclosures About Market Risk28Item4.Controls and Procedures28PARTII. OTHER INFORMATION29Item1.Legal Proceedings29Item1A. Risk Factors29Item2.Unregistered Sales of Equity Securities and Use of Proceeds29Item3.Defaults Upon Senior Securities29Item4.Mine Safety Disclosures29Item5.Other Information29Item6.Exhibits30Signatures31 PART I. FINANCIAL INFORMATION MaxCyte,Inc.Unaudited Condensed Consolidated Statements of Operations(in thousands, except share and per share amounts) MaxCyte,Inc.Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity(in thousands, except share amounts) MaxCyte,Inc.Unaudited Condensed Consolidated Statements of Cash Flows(in thousands) MaxCyte, Inc.Notes to Unaudited Condensed Consolidated Financial Statements(in thousands, except par value, share and per share amounts) 1.Organization and Description of Business MaxCyte, Inc. (the “Company” or “MaxCyte”) was incorporated as a majority-owned subsidiary ofEntreMed, Inc. (“EntreMed”) on July 31, 1998, under the laws and provisions of the State of Delaware andcommenced operations on July 1, 1999. In November 2002, MaxCyte was recapitalized, and EntreMedwas no longer deemed to control the Company. MaxCyte is a global life sciences company focused on advancing the discovery, development, andcommercialization of next-generation cell therapies. MaxCyte leverages its proprietary cell engineeringtechnology platform to enable the programs of its biotechnology and pharmaceutical company customerswho are engaged in cell therapy, including gene-editing and immuno-oncology, as well as in drugdiscovery and development and biomanufacturing. The Company licenses and sells its instruments andtechnology, sells its related processing assemblies (“PAs”) and consumables, and provides on target andoff-targetgene-editing assessment services(“Assay Services”)for cell and gene therapies.TheCompany’s customers include developers of cell therapies, pharmaceutical companies and biotechnologycompanies for use in drug discovery and development and biomanufacturing. 2.Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudit